Seribantumab
{{Infobox drug | Watchedfields = changed | verifiedrevid = 470603044 | IUPAC_name = (2S)-2-amino-3-(4-{[2-amino-3-(4-hydroxyphenyl)propanoyl]amino}phenyl)propanoic acid | image = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_category = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = | ChemSpider = | UNII = | KEGG = | ChEMBL = | synonyms = }}
Seribantumab is an experimental monoclonal antibody designed for the treatment of cancer. It specifically targets the ErbB3 receptor, a member of the epidermal growth factor receptor (EGFR) family, which plays a significant role in the pathology of several types of cancer, including breast cancer, lung cancer, and ovarian cancer.
Development and Mechanism[edit | edit source]
Seribantumab works by inhibiting the activity of the ErbB3 receptor, which is often overexpressed in cancer cells. By blocking this receptor, seribantumab can interfere with the proliferative signaling pathways that promote cancer cell growth and survival.
The development of seribantumab has been part of a broader trend in cancer treatment focusing on targeted therapies, which aim to attack specific molecular targets associated with cancer, while sparing normal cells. This approach can potentially lead to treatments with higher efficacy and fewer side effects compared to traditional chemotherapy.
Clinical Trials[edit | edit source]
Seribantumab has been evaluated in various clinical trials for its effectiveness and safety in treating different types of cancers. These studies have explored its use as a single agent and in combination with other therapies.
Current Status[edit | edit source]
As of the last update, seribantumab has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) for public use. Research is ongoing, and the future of seribantumab will depend on the outcomes of ongoing and future clinical trials.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
